What is Expression Therapeutics?
Expression Therapeutics operates at the intersection of genetic medicine and advanced manufacturing, specializing in curative gene therapies for hemophilia A and innovative cell therapies for neuroendocrine tumors. The company distinguishes itself through its proprietary AI-driven discovery platform and a dedicated GMP manufacturing facility located in Cincinnati, Ohio. By maintaining end-to-end control over the therapeutic lifecycle, from initial research to final delivery, Expression Therapeutics ensures rigorous quality standards and operational efficiency. Their lead candidate, ET3, represents a significant advancement in gene therapy, designed to offer durable, long-term protection for patients, while their ADEPT-STAR platform provides a novel approach to treating complex oncological conditions.
How much funding has Expression Therapeutics raised?
Expression Therapeutics has raised a total of $416K across 2 funding rounds:
Debt
$150K
Debt
$266K
Debt (2020): $150K with participation from PPP
Debt (2021): $266K led by PPP
Key Investors in Expression Therapeutics
PPP
Public-Private Partnership
What's next for Expression Therapeutics?
With the successful completion of this late-stage financing, Expression Therapeutics is well-positioned to scale its clinical operations and advance its lead assets through critical regulatory milestones. The strategic allocation of this capital will likely focus on expanding the manufacturing capacity of their Cincinnati facility and accelerating the clinical trial progression for the ET3 gene therapy program. As the company transitions toward potential commercialization, the focus will remain on validating the efficacy of their ADEPT-STAR platform in broader patient populations. Investors are closely monitoring the firm's ability to maintain its competitive edge in the gene therapy landscape, particularly as it navigates the complexities of late-stage clinical development and prepares for future market entry.
See full Expression Therapeutics company page
